| 1. |
- Brown, Darron R., et al.
(författare)
-
The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Naive Women Aged 16-26 Years
- 2009
-
Ingår i: Journal Of Infectious Diseases. - : Oxford University Press (OUP). - 0022-1899 .- 1537-6613. ; 199:7, s. 926-935
-
Konferensbidrag (refereegranskat)abstract
- Background. Human papillomavirus (HPV)-6/11/16/18 vaccine reduces the risk of HPV-6/11/16/18-related cervical intraepithelial neoplasia (CIN) 1-3 or adenocarcinoma in situ (AIS). Here, its impact on CIN1-3/AIS associated with nonvaccine oncogenic HPV types was evaluated. Methods. We enrolled 17,622 women aged 16-26 years. All underwent cervicovaginal sampling and Pap testing at regular intervals for up to 4 years. HPV genotying was performed for biopsy samples, and histological diagnoses were determined by a pathology panel. Analyses were conducted among subjects who were negative for 14 HPV types on day 1. Prespecified analyses included infection of >= 6 months' duration and CIN1-3/AIS due to the 2 and 5 most common HPV types in cervical cancer after HPV types 16 and 18, as well as all tested nonvaccine types. Results. Vaccination reduced the incidence of HPV-31/45 infection by 40.3% (95% confidence interval [CI], 13.9% to 59.0%) and of CIN1-3/AIS by 43.6% (95% CI, 12.9% to 64.1%), respectively. The reduction in HPV-31/33/45/52/58 infection and CIN1-3/AIS was 25.0% (95% CI, 5.0% to 40.9%) and 29.2% (95% CI, 8.3% to 45.5%), respectively. Efficacy for CIN2-3/AIS associated with the 10 nonvaccine HPV types was 32.5% (95% CI, 6.0% to 51.9%). Reductions were most notable for HPV-31. Conclusions. HPV-6/11/16/18 vaccine reduced the risk of CIN2-3/AIS associated with nonvaccine types responsible for similar to 20% of cervical cancers. The clinical benefit of cross-protection is not expected to be fully additive to the efficacy already observed against HPV-6/11/16/18-related disease, because women may have >1 CIN lesion, each associated with a different HPV type.
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
- Wheeler, Cosette M., et al.
(författare)
-
The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Sexually Active Women Aged 16-26 Years
- 2009
-
Ingår i: Journal Of Infectious Diseases. - : Oxford University Press (OUP). - 0022-1899 .- 1537-6613. ; 199:7, s. 936-944
-
Konferensbidrag (refereegranskat)abstract
- Background. We evaluated the impact of a quadrivalent human papillomavirus (HPV) vaccine on infection and cervical disease related to 10 nonvaccine HPV types (31, 33, 35, 39, 45, 51, 52, 56, 58, and 59) associated with >20% of cervical cancers. The population evaluated included HPV-naive women and women with preexisting HPV infection and/or HPV-related disease at enrollment. Methods. Phase 3 efficacy studies enrolled 17,622 women aged 16-26 years. Subjects underwent cervicovaginal sampling and Pap testing on day 1 and then at 6-12-month intervals for up to 4 years. HPV typing was performed on samples from enrollment and follow-up visits, including samples obtained for diagnosis or treatment of HPV-related disease. All subjects who received >= 1 dose and returned for follow-up were included. Results. Vaccination reduced the rate of HPV-31/33/45/52/58 infection by 17.7% (95% confidence interval [CI], 5.1% to 28.7%) and of cervical intraepithelial neoplasia (CIN) 1-3 or adenocarcinoma in situ (AIS) by 18.8% (95% CI, 7.4% to 28.9%). Vaccination also reduced the rate of HPV-31/58/59-related CIN1-3/AIS by 26.0% (95% CI, 6.7% to 41.4%), 28.1% (95% CI, 5.3% to 45.6%), and 37.6% (95% CI, 6.0% to 59.1%), respectively. Although a modest reduction in HPV-31/33/45/52/58-related CIN2 or worse was observed, the estimated reduction was not statistically significant. Conclusions. These cross-protection results complement the vaccine's prophylactic efficacy against disease associated with HPV-6, -11, -16, and - 18. Long-term monitoring of vaccinated populations are needed to fully ascertain the population-based impact and public health significance of these findings.
|
|
| 9. |
- Capilla, R., et al.
(författare)
-
Dynamic Variability Management Supporting Operational Modes of a Power Plant Product Line
- 2016
-
Ingår i: 10th International Workshop on Variability Modelling of Software-Intensive Systems, VaMoS 2016; Federal University of BahiaSalvador; Brazil; 27 January 2016 through 29 January 2016. - New York, NY, USA : ACM. ; 27-29-January-2016, s. 49-56
-
Konferensbidrag (refereegranskat)abstract
- Runtime variability is becoming an attractive technique to support those runtime scenarios for systems that demand some kind of autonomous reconfiguration or adaptive behavior. Nowadays, the challenge of many critical systems that need to handle different operational modes, often in an unattended mode, require specific solutions for which runtime variability mechanisms become relevant. This research describes the challenges of runtime variability to support multiple binding modes for handling the diversity of different operational modes and runtime reconfiguration needs. We validate our approach in a power plant control product line at Toshiba which advances previous work making the transition between the power plant operational modes more automatic and dynamic.
|
|
| 10. |
- Dos Santos, Rodrigo Pereira, et al.
(författare)
-
Introduction to 12th workshop on distributed software development, software ecosystems and systems-of-systems (WDES@ECSA 2018)
- 2018
-
Ingår i: ACM International Conference Proceeding Series.
-
Konferensbidrag (refereegranskat)abstract
- Systems-of-Systems (SoS) have become increasingly complex and used in highly distributed, dynamic, and even open environments. SoS refer to evolving software systems, where constituent systems work cooperatively to fulfill complex missions, facing software architecture researchers/practitioners with substantial challenges. In parallel, Software Ecosystem (SECO) has become an important research topic, addressing social and business issues along with technical aspects of software architectures. SoS and SECO are closely related, also naturally distributed so as the distribution of development teams, along with the inherent difficulties of coordination and communication. In this scenario, Distributed Software Development (DSD) deals with distributed resources to reduce cost and reach new IT markets. Inherent problems and challenges of software engineering are amplified and become more critical when those three topics need to be analyzed together. WDES 2018 will provide researchers and practitioners with a forum to exchange ideas and experiences, analyze R&D issues, discuss promising solutions, and propose theoretical foundations for architecting complex systems, inspiring visions for the future of software engineering for SoS, SECO, and DSD.
|
|
